Zobrazeno 1 - 10
of 750
pro vyhledávání: '"BTK inhibitors"'
Autor:
Shenmiao Yang, Rong Wei, Hongxia Shi, Yazhe Wang, Yueyun Lai, Xiaosu Zhao, Jin Lu, Norbert Schmitz
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundImpact of B-cell depletion following treatment with Bruton tyrosine kinase-inhibitors (BTKi) on the outcome of SARS-CoV-2 infection in chronic lymphocytic leukemia (CLL) patients remain controversial. We investigated the impact of BTKi on s
Externí odkaz:
https://doaj.org/article/52bacf232b7a4ca3ad3a874ac9edc844
Autor:
Mingyue Xu, Yunyu Xu, Li Yuan, Da Shang, Ruiying Chen, Shaojun Liu, Yan Li, Aiping Liu, Ruilai Liu, Qian Wang, Tianling Ding, Qionghong Xie, Chuan-Ming Hao
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
This study presents two cases of type II mixed cryoglobulinemia. One case is essential, while the other is presumably associated with hepatitis B virus (HBV) infection. Both patients tested positive for monoclonal IgMκ, but negative for MyD88 mutati
Externí odkaz:
https://doaj.org/article/0282b7a01af145709519db2eef8a81cd
Autor:
Marion Blaize, Guillaume Thizy, Alexandre Boissonnas, Anaïs Portalier, Fanny Lanternier, Clémentine de La Porte des Vaux, Felipe Suarez, Marie-Elisabeth Bougnoux, Juliette Guitard, Arnaud Jabet, Nicolas Stocker, Abdelmalek Aoudjhane, Damien Roos-Weil, Arnaud Fekkar
Publikováno v:
International Journal of Infectious Diseases, Vol 142, Iss , Pp 107000- (2024)
Objectives: Ibrutinib, a first-generation covalent Bruton's tyrosine kinase inhibitor (BTKi) was found to be a risk factor for the occurrence of invasive fungal complications. Acalabrutinib is a second-generation covalent BTKi used to treat B-cell ma
Externí odkaz:
https://doaj.org/article/f390dee4838949199893535f4082b903
Publikováno v:
BMC Ophthalmology, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background Vitreoretinal lymphoma (VRL) is usually treated with a combination of intraocular methotrexate (ioMTX), high-dose intravenous methotrexate (HD-MTX), or local radiotherapy (RT) as the first options. The effectiveness and safety of
Externí odkaz:
https://doaj.org/article/aee0c012778f427aa07d3e0cfc47bd2d
Autor:
Yuqin Song, Shang-Ju Wu, Zhixiang Shen, Donglu Zhao, Thomas Sau Yan Chan, Huiqiang Huang, Lugui Qiu, Jianyong Li, Tran-der Tan, Jun Zhu, Yongping Song, Wei-Han Huang, Weili Zhao, Herman Sung Yu Liu, Wei Xu, Naizhi Chen, Jun Ma, Cheng-Shyong Chang, Eric Wai Choi Tse
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-26 (2023)
Abstract Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good cl
Externí odkaz:
https://doaj.org/article/910b3c2480ed4cd4b9096ea9dadac833
Publikováno v:
Leukemia Research Reports, Vol 21, Iss , Pp 100459- (2024)
Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in the US, representing approximately 1.1% of all new cancers diagnosed. Most patients with CLL can be monitored without treatment, and the indicated treatment options include a C
Externí odkaz:
https://doaj.org/article/31dc3e0bf8014b1a8cc44379d0933a08
Autor:
Mourad Aloui, Mohammed Er-rajy, Hamada Imtara, Amina Goudzal, Sara Zarougui, Mohamed El fadili, David E. Arthur, Ramzi A. Mothana, Omar M. Noman, Mahmoud Tarayrah, Elhalaoui Menana
Publikováno v:
Saudi Pharmaceutical Journal, Vol 32, Iss 1, Pp 101911- (2024)
In recent years, there has been a focus on developing and discovering novel Bruton's tyrosine kinase (BTK) inhibitors, as they offer an effective treatment strategy for B-cell malignancies. BTK plays a crucial role in B cell receptor (BCR)-mediated a
Externí odkaz:
https://doaj.org/article/cb540ee5dbb2472887af86fdeefc4396
Autor:
Ying Zhou, Xiaohong Xu
Publikováno v:
Hematology, Vol 27, Iss 1, Pp 105-112 (2022)
The prognosis of patients with relapsed and refractory primary central nervous system diffuse large B cell lymphoma (PCNSL) is poor and there is no standard salvage treatment currently available. Gene expression profiling and next-generation sequenci
Externí odkaz:
https://doaj.org/article/4ddf663691af4631a1d9d4833867f0df
Publikováno v:
Hemato, Vol 3, Iss 4, Pp 758-770 (2022)
Bing–Neel syndrome (BNS) is a rare neurological complication of Waldenström macroglobulinaemia. We highlight key issues in clinical presentation, diagnosis, and treatment while focusing on new and emerging therapies available for patients diagnose
Externí odkaz:
https://doaj.org/article/797bf651db2b47a593055d468100f8a1
Publikováno v:
Journal of Inflammation Research, Vol Volume 15, Pp 6427-6438 (2022)
Tingyu Cao,1 Zengguang Wang,2 Xiaodong Zhu1 1Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China; 2Department of Neurosurgery, Tianjin Neurological Institute, Tia
Externí odkaz:
https://doaj.org/article/d776f61213564b4bad6a1f3d850b2ec2